Breckenridge 因潜在金属污染在美国全国消费者层面自愿召回一批 60 mg 盐酸普萘洛尔缓释胶囊
Breckenridge Pharmaceutical, Inc. Issues Voluntary Nationwide Consumer-Level Recall of One Lot of Propranolol Hydrochloride Extended-Release Capsules, USP, 60 mg, Due to Potential Metal Contamination
Breckenridge 于 2026 年 11 月 16 日公告,因潜在金属污染自愿召回一批 60 mg 盐酸普萘洛尔缓释胶囊,召回至美国消费者层面。
材料列出受影响批号、规格、有效期和分销时间,可用于核对本次消费者层面召回的具体产品范围。
COMPANY ANNOUNCEMENT
When a company announces a recall, market withdrawal, or safety alert, the FDA posts the company's announcement as a public service. FDA does not endorse either the product or the company.
Read Announcement View Product Photos
Summary
- Company Announcement Date:
- November 16, 2026
- FDA Publish Date:
- November 20, 2026
- Product Type:
- Drugs
- Reason for Announcement:
-
Recall Reason Description
Due to potential metal contamination
- Company Name:
- Breckenridge Pharmaceutical, Inc.
- Brand Name:
-
Brand Name(s)
Breckenridge
- Product Description:
-
Product Description
Propranolol Hydrochloride Extended-Release Capsules, USP, 60mg
Company Announcement
November 16, 2026— Breckenridge Pharmaceutical, Inc. (Breckenridge) is voluntarily recalling to the consumer level one lot of Propranolol Hydrochloride Extended-Release Capsules, USP, 60 mg, manufactured by Adare Pharma Solutions, due to potential metal contamination.
Risk Statement
Use of product from the affected lot could potentially cause lacerations of soft tissues in the oral cavity, esophagus, stomach, or intestine. The affected lot shared intermediate material suspected to be the source of metal contamination identified in a separate lot that was not released to market. To date, Breckenridge is not aware of any adverse events assessed to be related to this recall. Product from the affected lot subject to this recall was distributed nationwide to wholesalers and pharmacies between October 26, 2026 and November 04, 2026.
Recalled Product
Product | Package Size | NDC | Lot Number | Expiration Date |
|---|---|---|---|---|
Propranolol Hydrochloride | 100-count bottle | 51991-817-01 | PK25110035 | May 2029 |
What Consumers Should Do
Consumers should immediately stop taking product from the lot subject to this recall and contact their physician or healthcare provider for medical advice and replacement instructions. Consumers should return any unused portion of the affected product to the pharmacy where it was obtained.
Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this product.
Wholesalers, pharmacies, and other retail entities should check inventory for the recalled lot, quarantine any affected product, and not distribute or dispense the affected product. Entities that further distributed the product should notify their sub-accounts to the retail level.
For questions or concerns regarding this recall, contact Qualanex, Breckenridge’s designated recall service provider, Monday through Friday, 9:00 a.m. to 5:00 p.m. Eastern Time:
Phone: 1-855-736-0807
Email: recall@qualanex.com
Reporting Adverse Events
Adverse reactions or quality problems experienced with the use of this product may be reported to the U.S. Food and Drug Administration’s MedWatch Adverse Event Reporting program:
Online: www.fda.gov/medwatch/report.htm
Mail or fax: Download the reporting form at www.fda.gov/MedWatch/getforms.htm, or call 1-800-332-1088 to request a form. Complete and return the form to the address provided, or fax it to 1-800-FDA-0178.
This recall is being conducted with the knowledge of the U.S. Food and Drug Administration.
Company Contact Information
Consumers and recall inquiries:
1-855-736-0807
recall@qualanex.com
Media Contact:
Towa International / Breckenridge Pharmaceutical, Inc.
External Comm and IR team
Email: media@towapharmaceutical.com
Company Contact Information
- Consumers:
- Qualanex
- 1-855-736-0807
来源:FDA 官方药品与生物制品信息 · fda.gov